Breaking News

Frontage Expands Development Services

April 3, 2013

Gains broader DEA license for pain therapeutics and controlled-substances

Frontage Laboratories has received approval to expand its U.S. Drug Enforcement Agency (DEA) license to include formulation development and manufacture of GMP clinical trial materials (CTM) for pain therapeutics and controlled-substances. For the expanded DEA license, Frontage upgraded its facilities, security, and personnel procedures at both of its Exton, PA sites.
 
Frontage supports companies developing DEA Schedules I–V controlled substances and provides analytical development and GMP analytical testing, clinical trial services and bioanalytical support of clinical and preclinical samples.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important